Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PD-L1 expression in human cancers and its association with clinical outcomes
Jinming Yu, Xin Wang, Feifei Teng, et al.
OncoTargets and Therapy (2016) Vol. Volume 9, pp. 5023-5039
Open Access | Times Cited: 691

Showing 1-25 of 691 citing articles:

Immune-related adverse events of checkpoint inhibitors
Manuel Ramos‐Casals, Julie R. Brahmer, Margaret K. Callahan, et al.
Nature Reviews Disease Primers (2020) Vol. 6, Iss. 1
Open Access | Times Cited: 1012
T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
Patrick A. Ott, Yung‐Jue Bang, Sarina A. Piha‐Paul, et al.
Journal of Clinical Oncology (2018) Vol. 37, Iss. 4, pp. 318-327
Closed Access | Times Cited: 789
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Luc Dirix, István Takács, Guy Jérusalem, et al.
Breast Cancer Research and Treatment (2017) Vol. 167, Iss. 3, pp. 671-686
Open Access | Times Cited: 670
Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer Patients
Marie‐Nicole Theodoraki, Saigopalakrishna S. Yerneni, Thomas K. Hoffmann, et al.
Clinical Cancer Research (2017) Vol. 24, Iss. 4, pp. 896-905
Open Access | Times Cited: 559
PD‐1/PD‐L1 pathway: Basic biology and role in cancer immunotherapy
Arash Salmaninejad, Saeed Farajzadeh Valilou, Arezoo Gowhari Shabgah, et al.
Journal of Cellular Physiology (2019) Vol. 234, Iss. 10, pp. 16824-16837
Closed Access | Times Cited: 383
Recent advances in nanomaterial-based synergistic combination cancer immunotherapy
Wei Sang, Zhan Zhang, Yunlu Dai, et al.
Chemical Society Reviews (2019) Vol. 48, Iss. 14, pp. 3771-3810
Closed Access | Times Cited: 349
Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment
Oladapo O. Yeku, Terence J. Purdon, Mythili Koneru, et al.
Scientific Reports (2017) Vol. 7, Iss. 1
Open Access | Times Cited: 341
Beyond immune checkpoint blockade: emerging immunological strategies
Shawn P. Kubli, Thorsten Berger, Daniel Vilarim Araújo, et al.
Nature Reviews Drug Discovery (2021) Vol. 20, Iss. 12, pp. 899-919
Closed Access | Times Cited: 339
Recent Progresses in Phototherapy‐Synergized Cancer Immunotherapy
Chee Wee Ng, Jing Li, Kanyi Pu
Advanced Functional Materials (2018) Vol. 28, Iss. 46
Open Access | Times Cited: 317
Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms
İbrahim Halil Şahin, Mehmet Akce, Olatunji B. Alese, et al.
British Journal of Cancer (2019) Vol. 121, Iss. 10, pp. 809-818
Open Access | Times Cited: 312
Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis
Danielle Benedict Sacdalan, Josephine Anne Lucero, Dennis L. Sacdalan
OncoTargets and Therapy (2018) Vol. Volume 11, pp. 955-965
Open Access | Times Cited: 276
The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
Tang Qing, Yun Chen, Xiaojuan Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 276
Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion
Peixin Dong, Ying Xiong, Junming Yue, et al.
Frontiers in Oncology (2018) Vol. 8
Open Access | Times Cited: 267
Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells
Łukasz Skalniak, Krzysztof M. Zak, Katarzyna Guzik, et al.
Oncotarget (2017) Vol. 8, Iss. 42, pp. 72167-72181
Open Access | Times Cited: 248
Hsa_circ_0020397 regulates colorectal cancer cell viability, apoptosis and invasion by promoting the expression of the miR‐138 targets TERT and PD‐L1
Xiu‐li Zhang, Ling‐ling Xu, Fang Wang
Cell Biology International (2017) Vol. 41, Iss. 9, pp. 1056-1064
Closed Access | Times Cited: 219
Pathology of triple negative breast cancer
Filippo Borri, Annarita Granaglia
Seminars in Cancer Biology (2020) Vol. 72, pp. 136-145
Closed Access | Times Cited: 204
Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T
Dok Hyun Yoon, Mark J. Osborn, Jakub Tolar, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 2, pp. 340-340
Open Access | Times Cited: 198
Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion
Yi‐Ting Wang, Huanbin Wang, Han Yao, et al.
Frontiers in Pharmacology (2018) Vol. 9
Open Access | Times Cited: 195
Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients
Chuling Li, Chuwei Li, Chunchun Zhi, et al.
Journal of Translational Medicine (2019) Vol. 17, Iss. 1
Open Access | Times Cited: 192
Lactate modulates CD4+ T-cell polarization and induces an immunosuppressive environment, which sustains prostate carcinoma progression via TLR8/miR21 axis
Giuseppina Comito, Anthony Iscaro, Marina Bacci, et al.
Oncogene (2019) Vol. 38, Iss. 19, pp. 3681-3695
Closed Access | Times Cited: 178
c-Met and PD-L1 on Circulating Exosomes as Diagnostic and Prognostic Markers for Pancreatic Cancer
Alexander Lux, Christoph Kahlert, Robert Grützmann, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 13, pp. 3305-3305
Open Access | Times Cited: 148
Characterizing the molecular regulation of inhibitory immune checkpoints with multimodal single-cell screens
Efthymia Papalexi, Eleni P. Mimitou, Andrew Butler, et al.
Nature Genetics (2021) Vol. 53, Iss. 3, pp. 322-331
Open Access | Times Cited: 145
Microfluidic-based exosome isolation and highly sensitive aptamer exosome membrane protein detection for lung cancer diagnosis
Liang Zhao, Hong Wang, Jun Fu, et al.
Biosensors and Bioelectronics (2022) Vol. 214, pp. 114487-114487
Open Access | Times Cited: 94
Predictive biomarkers of colon cancer immunotherapy: Present and future
Wanting Hou, Yi Cheng, Hong Zhu
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 89
Cytokine release syndrome and cancer immunotherapies – historical challenges and promising futures
Deep Shah, Brian W. Soper, Lindsay S. Shopland
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 41
Page 1 - Next Page

Scroll to top